Author

B. Alman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

J. Somarelli· 2 shared A. Krez· 1 shared C. A. Watson· 1 shared C. Vanhove· 1 shared D. Creytens· 1 shared D. G. Kirsch· 1 shared D. Sivaraj· 1 shared D. Tulkens· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Somarelli

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

LCP1 Regulates Cell Motility in Chondrosarcoma and Correlates with Metastatic Potential and Poor Patient Outcomes

C. A. Watson, J. T. Martin, M. Nakagawa, N. Guardino, T. Zou, E. Peairs, A. Krez, P. Nadesan, Z. Huang, J. Ou, J. Somarelli, B. Alman, J. D. Visgauss

This study identifies LCP1 as a driver of metastasis and poor prognosis in chondrosarcoma through gene expression analysis and in vitro experiments.

bioRxiv · Jan 31, 2023 · PreprintCancer Biology

Loss of the chromatin remodeler, ATRX, promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin receptor binding

S. Bartholf DeWitt, S. Hoskinson Plumlee, H. E. Brighton, D. Sivaraj, E. J. Martz, M. Zand, V. Kumar, M. U. Sheth, W. Floyd, J. Spruance, N. Hawkey, S. Varghese, J. Ruan, D. G. Kirsch, J. Somarelli, , W. C. Eward

This study shows that loss of ATRX in osteosarcoma promotes aggressive tumor features through NF-κB signaling and integrin receptor binding, suggesting new therapeutic targets.

bioRxiv · Apr 22, 2022 · PreprintCancer Biology

CRISPR-SID: identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping

T. Naert, D. Tulkens, T. Van Nieuwenhuysen, J. Przybyl, S. Demuynck, M. van de Rijn, M. Al Jazrawe, B. Alman, P. J. Coucke, K. De Leeneer, C. Vanhove, S. N. Savvides, D. Creytens, K. Vleminckx

This paper introduces CRISPR-SID, a method to identify tumor dependencies in Xenopus models, revealing EZH2 as a druggable target for desmoid tumors.

bioRxiv · Sep 1, 2021Cancer Biology